C11orf46 Inhibitors
C11orf46 inhibitors constitute a diverse group of compounds that exert their inhibitory effects through interference with specific signaling cascades. For instance, LY294002 and Wortmannin target the PI3K enzyme, a pivotal element of the PI3K/Akt signaling pathway. The functional activity of C11orf46 is potentially contingent on the phosphorylation events mediated by Akt. By impeding PI3K's ability to catalyze the conversion of PIP2 to PIP3, these inhibitors stymie Akt activation, which in turn could lead to the inhibition of any downstream effectors, including C11orf46.
Compounds like U0126 and PD98059, which are well-known MEK inhibitors, would affect C11orf46 if it is linked to the MAPK/ERK pathway. These inhibitors specifically block the activation of MEK, which is upstream of ERK. This prevention of ERK phosphorylation and subsequent activation would result in reduced signaling through the MAPK/ERK pathway. Since this pathway is involved in a wide array of cellular processes, including growth and differentiation, the inhibition of MEK could lead to a decrease in C11orf46 activity if it is regulated by or is a part of this pathway.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of PI3K, LY294002 binds to the ATP-binding site of the enzyme, preventing its activity. If C11orf46 is functionally linked to the PI3K/Akt pathway, LY294002's inhibition of PI3K would reduce the phosphorylation and activation of Akt, thereby leading to the inhibition of C11orf46 if it is downstream of Akt signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin irreversibly inhibits PI3K by covalently binding to the enzyme. This inhibition would prevent the activation of the PI3K/Akt pathway. If C11orf46 requires PI3K/Akt pathway activity for its function, inhibition by Wortmannin would result in decreased functional activity of C11orf46. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a highly selective inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. By inhibiting MEK, U0126 prevents the activation of ERK. If C11orf46 is regulated by the MAPK/ERK pathway, inhibition of this pathway would block the signaling events necessary for C11orf46 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As a selective inhibitor of MEK, PD98059 prevents the phosphorylation and activation of MEK targets, including ERK. If C11orf46 operates downstream of the MAPK/ERK pathway, PD98059's inhibition of MEK would lead to a reduction in C11orf46 functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK. If C11orf46 is activated by or dependent on the p38 MAPK pathway, the inhibition of p38 MAPK by SB203580 would lead to decreased functional activity of C11orf46. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, a central component of the mTOR signaling pathway. If C11orf46's activity is connected to mTOR signaling, inhibition of mTOR by Rapamycin would decrease C11orf46 activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR. It inhibits both mTORC1 and mTORC2 complexes. If C11orf46 is regulated by mTOR signaling pathways, PP242 would inhibit these and thereby decrease the functional activity of C11orf46. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in apoptosis and cell proliferation. If C11orf46 is functionally linked to the JNK pathway, inhibition by SP600125 would lead to decreased activity of C11orf46. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits Akt. By doing so, it prevents downstream signaling required for cell survival and proliferation. If C11orf46 is downstream of Akt, its activity would be reduced upon Akt inhibition. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an ATP-competitive inhibitor of Akt. By inhibiting Akt, it disrupts signaling downstream of PI3K. If C11orf46 relies on Akt signaling, GSK690693 would lead to decreased C11orf46 activity. | ||||||